Wells Fargo Upgrades Biogen to Overweight Amid Confidence in New Pipeline Programs
Wells Fargo upgraded Biogen (BIIB) to Overweight with a $250 price target, citing confidence in its late-stage immunology and kidney pipeline programs as growth drivers beyond its declining Alzheimer’s and MS franchises. The upgrade reflects Wall Street's growing belief in Biogen's revenue diversification and transformation away from its struggling neurological businesses.
Topics: Analyst Opinion Biogen Pipeline Development Stock Upgrade Wells Fargo